Skyrizi vs. Otezla

• Are Skyrizi and Otezla the Same Thing?
• What Are Possible Side Effects of Skyrizi?
• What Are Possible Side Effects of Otezla?
• What Is Skyrizi?
• What Is Otezla?
• What drugs interact with Skyrizi?
• What drugs interact with Otezla?
• How Should Skyrizi Be Taken?
• How Should Otezla Be Taken?

Skyrizi (risankizumab-rzaa) and Otezla (apremilast) are used to treat different types of psoriasis.

Skyrizi is used to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Otezla is used to treat adult patients with active psoriatic arthritis.

Skyrizi and Otezla belong to different drug classes. Skyrizi is an interleukin-23 antagonist and Otezla is a phosphodiesterase 4 (PDE4) inhibitor.

Side effects of Skyrizi and Otezla that are similar include upper respiratory infections, headache, and fatigue.

Side effects of Skyrizi that are different from Otezla include injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth) and tinea infections (such as ringworm, athlete's foot, and jock itch).

Side effects of Otezla that are different from Skyrizi include diarrhea, nausea, vomiting, runny or stuffy nose, abdominal pain, indigestion/heartburn, decreased appetite, insomnia, back pain, frequent bowel movements, depression, bronchitis, tooth abscess, sinus headache, weight loss, gastroesophageal reflux disease (GERD), migraine, cough, and rash.

Skyrizi may interact with "live" vaccines.

Otezla may interact with CYP450 inducers (such as rifampin, phenobarbital, carbamazepine, and phenytoin).

Side effects of Skyrizi include:

• upper respiratory infections,
• headache,
• fatigue,
• injection site reactions (bruising, redness, fluid leakage, bleeding, infection, inflammation, irritation, pain, itching, swelling, warmth), and
• tinea infections (such as ringworm, athlete's foot and jock itch)

Common side effects of Otezla include:

• diarrhea,
• headache,
• nausea,
• upper respiratory tract infection,
• vomiting,
• runny or stuffy nose,
• abdominal pain,
• fatigue,
• indigestion/heartburn,
• decreased appetite,
• insomnia,
• back pain,
• frequent bowel movements,
• depression,
• bronchitis,
• tooth abscess, and
• sinus headache.

Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Otezla (apremilast) is a phosphodiesterase 4 (PDE4) inhibitor used to treat adult patients with active psoriatic arthritis.

 

Skyrizi may interact with "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Skyrizi; it is unknown how it would affect a fetus. It is unknown if Skyrizi passes into breast milk. Consult your doctor before breastfeeding.

Otezla may interact with CYP450 inducers (such as rifampin).

 

The dose of Skyrizi is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4 and every 12 weeks thereafter.

The recommended maintenance dosage is 30 mg twice daily taken orally starting on Day 6, after 5 days of an initial schedule of titration dosing.